简体
简体中文
繁體中文

Arin战术极端风险主动型ETF ATTR

等待开盘 07-07 09:30:00 美东时间

94.3829

+0.294

+0.31%

华盛通华盛通
立即下载
  • 最 高94.3829
  • 今 开94.0889
  • 成交量 105股
  • 最 低 94.3829
  • 昨 收 94.0889
  • 总市值 9335.41万
  • 52周最高 94.4739
  • 市盈率 --
  • 换手率 0.01%
  • 52周最低 88.71
  • 委 比 0.00%
  • 总股本 98.91万
  • 历史最高 94.4739
  • 量 比 0
  • 振 幅 0.00%
  • 历史最低 88.71
  • 每 手 1
  • 风险率 1.50%

个股概要

财务分析

公司资料

相关新闻

分红派息

  • 分时图
  • 日k
  • 周k
  • 月k

相关新闻

更多
  • After the fracture: how Britain's financial industry recovered from Brexit

    After the fracture: how Britain's financial industry recovered from Brexit London's finance sector lost global market share and jobs post-Brexit, data shows Rising interest rates and deregulation have boosted bank and insurance profits European Union has failed to capitalise, Britain still competiti

    06-21 16:00

  • BRIEF-DKSH Enters Strategic Distribution Partnership With Bridgebio

    BRIEF-DKSH Enters Strategic Distribution Partnership With Bridgebio June 11 (Reuters) - DKSH Holding AG DKSH.S : DKSH ENTERS STRATEGIC DISTRIBUTION PARTNERSHIP WITH BRIDGEBIO BBIO.O TO SUPPORT REGULATORY EVALUATION AND POTENTIAL PATIENT ACCESS TO TRANSTHYRETIN STABILIZER FOR ATTR-CM IN SELECTED ASIA

    06-11 13:04

  • Mark Carney's trade push collides with reality of US dependence

    Mark Carney's trade push collides with reality of US dependence Canada's access to USMCA remains main attraction in its bid to woo foreign investors Japanese, Swedish, South Korean carmakers lobby to maintain access to US markets through Canada Canada is focused on Pacific trade deals, but Asian lea

    06-09 13:00

  • BRIEF-Fuji Media’s Real Estate Unit Sankei Building Co Attracts 1 Trillion Yen Bids - Bloomberg News

    BRIEF-Fuji Media’s Real Estate Unit Sankei Building Co Attracts 1 Trillion Yen Bids - Bloomberg News June 4 (Reuters) - FUJI MEDIA’S REAL ESTATE UNIT SANKEI BUILDING CO ATTRACTS 1 TRILLION YEN BIDS - BLOOMBERG NEWS Source text: https://bit.ly/4fJePVp Further company coverage: 4676.T (( Reuters.Brief

    06-04 16:54

  • UPDATE 1-CANAL+ becomes first French company to list in Johannesburg

    UPDATE 1-CANAL+ becomes first French company to list in Johannesburg CANAL+ aims to broaden shareholder base, boost liquidity via JSE listing Broadcaster secures new sports rights deals via SuperSport JSE chairman says listing shows global confidence in South Africa's markets Recasts with CEO's comm

    06-03 22:23

  • BridgeBio publishes corporate presentation outlining rare-disease pipeline and 2026 milestones

    BridgeBio publishes corporate presentation outlining rare-disease pipeline and 2026 milestones BridgeBio highlighted Attruby (acoramidis) as approved for ATTR-CM, citing Q1 2026 net product revenue of USD 180.6 million. Presentation cited a 42% reduction in all-cause mortality and cardiovascular hos

    06-03 17:06

  • BridgeBio downgraded at Raymond James on LOE for Pfizer’s Vyndamax

    Shares of BridgeBio Pharma (BBIO) slipped in the premarket on Tuesday after Raymond James downgraded the stock, citing the impact from the loss of exclusivity for Pfizer’s (PFE) heart drug Vyndamax, w...

    05-26 21:25

  • BRIEF-Miniso Group Posts Qtrly Profit Attributable Of RMB1.25 Billion

    BRIEF-Miniso Group Posts Qtrly Profit Attributable Of RMB1.25 Billion May 26 (Reuters) - MINISO Group Holding Ltd 9896.HK : MINISO GROUP ANNOUNCES MARCH QUARTER 2026 UNAUDITED FINANCIAL RESULTS QTRLY REVENUE RMB5,688.4 MILLION QTRLY PROFIT ATTRIBUTABLE RMB1.25 BILLION Further company coverage: 9896.

    05-26 16:39

  • BRIEF-Ebay Rejects Unsolicited Proposal From Gamestop

    BRIEF-Ebay Rejects Unsolicited Proposal From Gamestop eBay Inc EBAY.O : EBAY REJECTS UNSOLICITED PROPOSAL FROM GAMESTOP EBAY: CONCLUDED THAT GAMESTOP PROPOSAL IS NEITHER "CREDIBLE NOR ATTRACTIVE" EBAY: BOARD IS CONFIDENT THAT CO, UNDER ITS CURRENT MANAGEMENT TEAM, IS WELL-POSITIONED TO CONTINUE TO

    05-12 18:01

  • Alnylam says HELIOS-B analysis shows vutrisiran benefit across ATTR-CM patient groups

    Alnylam says HELIOS-B analysis shows vutrisiran benefit across ATTR-CM patient groups Alnylam highlighted new analyses from HELIOS-B Phase 3 trial of vutrisiran in ATTR-CM, with results already presented at Heart Failure 2026. Analyses showed clinical benefit remained consistent across harder-to-tre

    05-12 14:30